That only helps them if they can make an exclusive deal in a particular region.
If one combination is more efficacious (such as perhaps OPT302 working even better with Eylea than with Lucentis), then it would make a very attractive treatment.
What matters most? Acuity or Duration? What if Opthea was wrong?, page-16
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add OPT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
41.0¢ |
Change
-0.005(1.20%) |
Mkt cap ! $504.7M | |||
| Open | High | Low | Value | Volume |
| 42.0¢ | 42.5¢ | 40.8¢ | $499.8K | 1.198M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 24187 | 41.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 42.0¢ | 20978 | 2 |
View Market Depth
| Last trade - 16.10pm 09/08/2024 (20 minute delay) ? |
| OPT (ASX) Chart |